Please login to the form below

Not currently logged in
Email:
Password:

postmenopausal osteoporosis

This page shows the latest postmenopausal osteoporosis news and features for those working in and with pharma, biotech and healthcare.

Evenity back on track with FDA panel blessing in osteoporosis

Evenity back on track with FDA panel blessing in osteoporosis

The panel backed the use of the drug in postmenopausal women with osteoporosis at high risk for fracture by 18-1. ... risk. Amgen’s R&D head Davide Reese said that having additional treatment options for postmenopausal women with osteoporosis is

Latest news

  • Amgen's Kyprolis scarred by head-to-head duel with Velcade Amgen's Kyprolis scarred by head-to-head duel with Velcade

    Romosozumab filed  . There was some better news for Amgen and partner UCB this week when the FDA started its review of romosozumab, their drug candidate for the treatment of osteoporosis in ... postmenopausal women at increased risk of fracture.

  • Merck decision to drop odanacatib lifts UCB/Amgen Merck decision to drop odanacatib lifts UCB/Amgen

    The company prematurely halted a phase III trial of the drug in 2012 after seeing a clear benefit on fractures rates in postmenopausal women with osteoporosis, although it did note at ... fractures in postmenopausal women with osteoporosis compared to

  • Amgen buys back product rights from GSK Amgen buys back product rights from GSK

    The US biopharma giant is reacquiring rights to denosumab - sold as Prolia for osteoporosis and Xgeva for bone metastases from solid tumours - and colorectal cancer therapy Vectibix (panitumumab). ... Meanwhile, Prolia received a boost recently after it

  • Merck & Co plays catch-up with osteoporosis data for odanacatib Merck & Co plays catch-up with osteoporosis data for odanacatib

    Says study shows significant reduced risk of osteoporotic symptoms. Merck &Co has revealed positive results from a phase III fracture outcomes study for odanacatib in postmenopausal women with osteoporosis. ... The study enrolled 16, 713 women aged 65

  • Onyx rejects $10bn takeover bid from Amgen Onyx rejects $10bn takeover bid from Amgen

    postmenopausal osteoporosis) while Aranesp failed to show efficacy in a phase III heart failure trial.

More from news
Approximately 1 fully matching, plus 28 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Fendix

Latest intelligence

NHS regional footprints
What to expect from 2019...
Not another weight-loss ad
Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...
China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...

Infographics